Ji Y - Search Results

1

Repurposing ketotifen as a therapeutic strategy for neuroendocrine prostate cancer by targeting the IL-6/STAT3 pathway.

Ji Y, Liu B, Chen L, Li A, Shen K, Su R, Zhang W, Zhu Y, Wang Q, Xue W. Ji Y, et al. Cell Oncol (Dordr). 2023 Oct;46(5):1445-1456. doi: 10.1007/s13402-023-00822-9. Epub 2023 Apr 29. Cell Oncol (Dordr). 2023. PMID: 37120492

2

HOXD13 suppresses prostate cancer metastasis and BMP4-induced epithelial-mesenchymal transition by inhibiting SMAD1.

Xu F, Shangguan X, Pan J, Yue Z, Shen K, Ji Y, Zhang W, Zhu Y, Sha J, Wang Y, Fan L, Dong B, Wang Q, Xue W. Xu F, et al. Among authors: ji y. Int J Cancer. 2021 Jun 15;148(12):3060-3070. doi: 10.1002/ijc.33494. Epub 2021 Mar 6. Int J Cancer. 2021. PMID: 33521930

3

SUMOylation controls the binding of hexokinase 2 to mitochondria and protects against prostate cancer tumorigenesis.

Shangguan X, He J, Ma Z, Zhang W, Ji Y, Shen K, Yue Z, Li W, Xin Z, Zheng Q, Cao Y, Pan J, Dong B, Cheng J, Wang Q, Xue W. Shangguan X, et al. Among authors: ji y. Nat Commun. 2021 Mar 22;12(1):1812. doi: 10.1038/s41467-021-22163-7. Nat Commun. 2021. PMID: 33753739 Free PMC article.

4

The Evolving Role of ¹⁸F-FDG PET/CT in Diagnosis and Prognosis Prediction in Progressive Prostate Cancer.

Shen K, Liu B, Zhou X, Ji Y, Chen L, Wang Q, Xue W. Shen K, et al. Among authors: ji y. Front Oncol. 2021 Jul 29;11:683793. doi: 10.3389/fonc.2021.683793. eCollection 2021. Front Oncol. 2021. PMID: 34395251 Free PMC article.

5

Downregulation of SHMT2 promotes the prostate cancer proliferation and metastasis by inducing epithelial-mesenchymal transition.

Chen L, Liu H, Ji Y, Ma Z, Shen K, Shangguan X, Qian H, Zhao Y, Pan CW, Xue W. Chen L, et al. Among authors: ji y. Exp Cell Res. 2022 Jun 15;415(2):113138. doi: 10.1016/j.yexcr.2022.113138. Epub 2022 Apr 7. Exp Cell Res. 2022. PMID: 35398308

6

Docetaxel remodels prostate cancer immune microenvironment and enhances checkpoint inhibitor-based immunotherapy.

Ma Z, Zhang W, Dong B, Xin Z, Ji Y, Su R, Shen K, Pan J, Wang Q, Xue W. Ma Z, et al. Among authors: ji y. Theranostics. 2022 Jun 27;12(11):4965-4979. doi: 10.7150/thno.73152. eCollection 2022. Theranostics. 2022. PMID: 35836810 Free PMC article.

7

Comprehensive analysis of androgen receptor status in prostate cancer with neuroendocrine differentiation.

Su R, Chen L, Jiang Z, Yu M, Zhang W, Ma Z, Ji Y, Shen K, Xin Z, Qi J, Xue W, Wang Q. Su R, et al. Among authors: ji y. Front Oncol. 2022 Aug 9;12:955166. doi: 10.3389/fonc.2022.955166. eCollection 2022. Front Oncol. 2022. PMID: 36033483 Free PMC article.

8

High-throughput drug screening identifies fluoxetine as a potential therapeutic agent for neuroendocrine prostate cancer.

Chen L, Ji Y, Li A, Liu B, Shen K, Su R, Ma Z, Zhang W, Wang Q, Zhu Y, Xue W. Chen L, et al. Among authors: ji y. Front Oncol. 2023 Mar 13;13:1085569. doi: 10.3389/fonc.2023.1085569. eCollection 2023. Front Oncol. 2023. PMID: 36994207 Free PMC article.

9

¹⁸ F-FDG PET/CT imaging in neuroendocrine prostate cancer: Relation to histopathology and prognosis.

Shen K, Yu M, Ji Y, Zhou X, Liu B, Zhang W, Su R, Qi J, Wang Q, Xue W. Shen K, et al. Among authors: ji y. Prostate. 2023 Sep;83(12):1167-1175. doi: 10.1002/pros.24559. Epub 2023 May 15. Prostate. 2023. PMID: 37189301

10

The ELAVL3/MYCN positive feedback loop provides a therapeutic target for neuroendocrine prostate cancer.

Ji Y, Zhang W, Shen K, Su R, Liu X, Ma Z, Liu B, Hu C, Xue Y, Xin Z, Yang Y, Li A, Jiang Z, Jing N, Zhu HH, Dong L, Zhu Y, Dong B, Pan J, Wang Q, Xue W. Ji Y, et al. Nat Commun. 2023 Nov 28;14(1):7794. doi: 10.1038/s41467-023-43676-3. Nat Commun. 2023. PMID: 38016952 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11,051 results

Search Page

Filters